<DOC>
	<DOCNO>NCT01455025</DOCNO>
	<brief_summary>This phase 1 , dose escalation study Plerixafor combination granulocyte-colony stimulate factor , Daunorubicin Cytarabine adult patient relapse acute myeloid leukemia .</brief_summary>
	<brief_title>Study Plerixafor Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia</brief_title>
	<detailed_description>The Primary objective determine maximal tolerate dose Recommended Phase 2 Dose plerixafor use combination granulocyte-colony stimulating factor , Daunorubicin Cytarabine induction therapy Then determine tolerability plerixafor administer combination G-CSF cytarabine consolidation therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients Acute Myeloid Leukemia first relapse first response duration &gt; 9 month . Age 18 65 year . Treatment hydroxyurea purinethol allow discontinue least 24 hour start study treatment . White blood count le 30 x 109/L Left ventricular ejection fraction 50 % echocardiography multigated acquisition scan similar radionuclide angiographic scan . Total bilirubin le 1.5 x upper limit normal= ULN AST ALT le 2.5 x ULN gammaGT le 2.5 x ULN . Serum creatinine le 1.5 x ULN and/or creatinine clearance 50 ml/mn . ECOG performance status le 2 Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule . Absence pregnancy lactation Affiliated French social security system similar Signed inform consent AML evolve MPD and/or secondary AML Patients treat 270 mg/m2 daunorubicin first line therapy . Have follow within last 9 month : Unstable supraventricular arrhythmia patient pacemaker Any ventricular arrhythmia Congestive heart failure Myocardial infarction , ischemia , stable coronary disease angina pectoris Syncope know cardiovascular etiology Known hypersensitivity contraindication drug use protocol = GCSF , daunorubicin , cytarabine excipients . Previous treatment plerixafor . Previous hematopoietic stem cell transplantation = Allologous autologous . White blood count 30 x 109/L despite treatment hydroxyurea purinethol . Treatment chemotherapy GCSF within 3 month screen . Uncontrolled active infection . Uncontrolled arrythmia Grade 3 renal dysfunction serum creatinine 1.5 x ULN and/or creatinine clearance le 50 ml/mn . Significant neurologic grade 2 psychiatric disorder , dementia seizure . Clinical symptom suggest active central nervous system leukemia . Preexisting disorder predispose patient serious lifethreatening infection = cystic fibrosis , congenital acquire immunodeficiency , bleed disorder cytopenia Thrombocytopenia refractory platelet transfusion Anticoagulant therapy Severe complication leukemia uncontrolled bleeding , pneumonia hypoxia shock disseminate intravascular coagulation . Thrombocytopenia refractory platelet transfusion . Prior total body irradiation 10 Gy . Known HIV , Hepatitis B C positivity . Participation clinical study investigational agent within 14 day study entry . Pregnancy breastfeed Adult patient protect law Concurrent treatment anticancer therapy except hydroxyurea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Plerixafor granulocyte-colony stimulating factor</keyword>
	<keyword>Chemotherapy relapse</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
</DOC>